logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 [see all tables in this series...]

Part (vii) Percentage amongst all clients with stimulants (other than cocaine) as primary drug

CountryInjectSmoke/inhaleEat/drinkSniffOthersBase (known status)Status unknown
Bulgaria0.00.028.657.114.370
Czech Republic73.21.12.123.50.194711
Denmark4.60.024.471.10.019768
Germany1.45.861.322.09.461699549
Ireland0.00.089.011.00.01361
Greece33.30.066.70.00.030
Spain(1)1.35.049.639.74.463519
France2.14.286.07.00.714349
Italy0.03.394.91.80.03920
Cyprus0.00.080.020.00.050
Lithuania61.52.226.79.60.01351
Luxembourg0.00.0100.00.00.0120
Hungary7.20.876.714.90.410380
Malta0.00.0100.00.00.041
Netherlands(2)1.17.037.052.92.156068
Slovakia35.325.14.333.81.42077
Finland76.21.211.311.30.040721
Sweden48.21.443.26.90.241954
United Kingdom(3)16.83.461.65.312.93845852
Total14.44.355.418.57.41526110701

Notes:

 Only countries where there are clients reported with stimulants as primary drug are shown. 

 (1) Data from Spain refer to 2004. 

 (2) Data refer to outpatient treatment centres and low-threshold agencies. 

 (3) Data refer to collection period between 01.04.2004 and 31.03.2005. 

 See also 'Table TDI-110' for cocaine CIH and crack route of administration distribution, and 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 2006 Reitox national reports - TDI - outpatient treatment centres. 

Page last updated: Monday, 12 November 2007